Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sun Pharma, Moebius...

    Sun Pharma, Moebius Medical ink pact to develop pain product

    Written by savita thakur thakur Published On 2016-12-13T11:14:54+05:30  |  Updated On 13 Dec 2016 11:14 AM IST
    Sun Pharma, Moebius Medical ink pact to develop pain product

    Sun Pharmaceutical Industries and Israel-based Moebius Medical have signed a global licensing pact to develop further an injection for treating osteoarthritis pain.


    The exclusive worldwide licensing deal is to further develop MM-II, a novel non-opioid pain product for osteoarthritis, the companies said in a joint statement.



    MM-II is an intra-articular biolubricant injection which is being developed to provide symptomatic relief of mild-to- moderate osteoarthritis pain, it said.

    "Sun Pharma will fund further development of Moebius Medical's lead product, MM-II, and undertake its global commercialisation," it added.

    Moebius Medical will conduct requisite pre-clinical studies and will assume responsibility for product development and manufacturing through the end of Phase-II studies, as per the pact, the statement said.

    Sun Pharma will assume responsibility for further clinical studies, regulatory submissions and product commercialisation, it added.

    "Moebius Medical will receive an upfront payment, development-based and sales-based milestone payments, and tiered royalties on sales from Sun Pharma," the statement said without mentioning any details about payments.

    Sun Pharma Global Head of Business Development Kirti Ganorkar said the agreement is "a part of our effort to build a branded product pipeline and enrich our global portfolio for pain products".

    The company is encouraged to further develop MM-II and hopes to bring a new innovative treatment to patients suffering from osteoarthritic pain, he added.

    "We are proud and excited that Sun Pharma...Has chosen Moebius Medical as a partner for building its specialty pipeline, and we look forward to close cooperation as we continue MM-II's development," Moebius Medical CEO Moshe Weinstein said.

    Sun Pharma's investment confirms the potential of Moebius Medical's innovative approach to bring effective pain relief to osteoarthritis patients, he added.

    To date, Moebius Medical has completed a first-in-man clinical study at Hadassah Medical Center, the statement said.


    Hadassah Medical Centerink pactMoebius Medicalopioidopioid pain productOsteoarthritispharma newsSun Pharma
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok